WorldStage Newsonline– Glaxosmithkline Consumer Nigeria Plc which is into manufacturing, marketing and distribution of consumer healthcare and pharmaceutical products has released its unaudited consolidated and separate financial statements for the period ended 30th September 2020 with 1.08% growth in revenue in the third quarter (July – September 2020) to N6.016 billion from N5.951 billion in Q3 2019.
The revenue for the first nine months of the year (Jan – September 2020) rose to N16.447 billion from N15.916 billion in 2019.
However, the total profit after tax for the Q3 dropped by 23.55% to N42.028 million from N54.977 million while profit for nine months rose to N434.321 million from N427.031 million
The Company is a public limited liability company incorporated in 1971 and domiciled in Nigeria where its shares are publicly traded. 46.4% of the shares of the Company are held by Setfirst Limited and Smithkline Beecham Limited (both incorporated in the United Kingdom); and 53.6% by Nigerian shareholders. The ultimate parent and ultimate controlling party is GlaxoSmithKline Plc, United Kingdom (GSK Plc UK).
GSK Plc UK controls the Company through Setfirst Limited and Smithkline Beecham Limited.
